Status:
COMPLETED
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
Lead Sponsor:
Belfast Health and Social Care Trust
Collaborating Sponsors:
Queen's University, Belfast
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Cystic fibrosis (CF) is a multisystem disease characterized by viscid secretions in multiple organ systems. Lung infection and damage account for most of the disease burden. Acute changes in respirato...
Detailed Description
Pulmonary Exacerbations in CF require treatment with intravenous (IV) antibiotics and hospital admission for between 10-21 days. These episodes cause substantial disruption to people's lives and impac...
Eligibility Criteria
Inclusion
- Patients attending the adult service with a confirmed diagnosis of CF by sweat test or genotype
- Able to provide written informed consent
- Able to understand and comply with protocol requirements and instructions
- Confirmed Pulmonary Exacerbation requiring treatment with intravenous antibiotics using defined criteria (Physician and patient agreed need for admission for intravenous antibiotic treatment)
Exclusion
- Previous recipient of a lung or other solid organ transplant
- Inability to complete questionnaires
- Current enrolment in other investigational medicinal product randomised trial
- Admission for reasons other than pulmonary exacerbation of CF
Key Trial Info
Start Date :
December 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2019
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04016571
Start Date
December 1 2016
End Date
March 1 2019
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Belfast Regional Adult CF Centre
Belfast, United Kingdom, BT9 7AE